VECTURA GROUP (LSE:VEC)

 

VECTURA GROUP (VEC.L, LSE, LSE:VEC)

VEC Share PerformanceMore

52 week high158.75 07/04/14
52 week low113.25 16/10/14
52 week change -7.75 (-5.05%)
4 week volume9,276,620 05/03/15

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Total Voting Rights

RNS Number: 0765J Vectura Group plc 01 April 2015 Vectura Group plc (the "Company") VOTING RIGHTS AND CAPITAL Chippenham, UK, 1 April 2015: In accordance with the Financial Conduct Authority's Transparency Directive, Transitional Provision6, Vectura Group plc (LSE: VEC) ("the Company") wishes to notify the market of the following: The Compa...

Appointment of Non-Executive Director

RNS Number: 0329J Vectura Group plc 01 April 2015 Vectura Group plc Appointment of Non-Executive Director Chippenham, UK - 1 April 2014: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces the appointment of Dr Per-Olof Andersson as a Non-Executive Director of the Board with immediate effect. Per-Olof has an international R&D tr...

Director/PDMR Shareholding

RNS Number: 2708H Vectura Group plc 12 March 2015 Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons All relevant boxes should be completed in block capital letters. 1. Name of the issuer 2. State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure m...

VEC says AirFluSal Forspiro launched in Portugal & Ireland

Vectura Group confirmed its partner Sandoz has announced the launch of AirFluSal Forspiro, an inhaler for patients with...

AirFluSal Forspiro launched in Portugal & Ireland

RNS Number: 1014H Vectura Group plc 11 March 2015 Vectura Group plc AirFluSal Forspiro launched in Portugal and Ireland 50-250 g and 50-500 g dosage forms launched in Portugal and Ireland Innovative inhaler offers asthma and COPD patients a new therapeutic option Now available to patients in 14 countries as the global roll-out continues apace Chippenham,...

NDA acceptance for QVA149 and NVA237

RNS Number: 6561G Vectura Group plc 05 March 2015 Vectura Group plc US FDA filing acceptance of NDAs for QVA149 and NVA237 Chippenham, UK - 5 th March 2015: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), confirms that Novartis' New Drug Applications (NDAs) for QVA149 and NVA237 for the long-term maintenance treatment of ch...

Voting Rights and Capital

RNS Number: 2183G Vectura Group plc 02 March 2015 Vectura Group plc (the "Company") VOTING RIGHTS AND CAPITAL Chippenham, UK, 2 March 2015: In accordance with the Financial Conduct Authority's Transparency Directive, Transitional Provision6, Vectura Group plc (LSE: VEC) ("the Company") wishes to notify the market of the following: The Co...

Holding(s) in Company

RNS Number: 5477E Vectura Group plc 10 February 2015 For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Vectura Group plc 2 Reason for the notification (please tick...